secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001477932-23-005435
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab Corp. completes 1-for-12 reverse stock split effective July 20, 2023
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-12 ratio effective July 20, 2023; prior 1-for-10 plan amended.
- No fractional shares; odd lots under 100 shares rounded up to nearest whole share or 100 shares.
- Authorized shares unchanged at 300M common and 30M preferred; par value unchanged.
- New CUSIP following split: 090628207.
- Split approved by stockholders and board on May 8, 2023; FINRA announced July 19, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793223005435/0001477932-23-005435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793223005435/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-005435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer